ABCL

AbCellera Biologics Inc. (ABCL) | Rumor.io

AbCellera Biologics

ABCL

Attention (50-day avg)0.1%

Attention rank (50-day avg)#99

Bullish sentiment (50-day avg)89%

Price to earnings ratio-28.4

Market capitalization4.5B

Earnings per share-0.54

Dividend yield (TTM)—

Revenue (annual)75.1M

Net income (annual)-146.4M

Social

What share of all stock conversation is about ABCL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.24% -0.06	0.13% +0.05	0.07% -0.07	0.03% -0.01

Sep 29

JPMorgan initiates coverage of AbCellera with an Overweight rating and a $17 price target, citing the company's differentiated technology platform and partnerships.
AbCellera's lead NK3R antagonist internal program for menopausal hot flashes has shown strong efficacy and safety results, with the firm believing the stock "stands at a major value inflection point".
AbCellera aims to have 5 molecules in the clinic by the middle of next year, with 4 more programs than currently in the clinic, and is making progress in IND-enabling studies.

Generated by AI

Sentiment

Of the messages about ABCL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	98.39% +27.56	89.56% -6.43	90.35% +2.35	91.42% -3.21
Bearish	1.61% -27.56	10.44% +6.43	9.65% -2.35	8.58% +3.21

Bullish· Sep 29

JPMorgan has initiated a price target of $17 for AbCellera Biologics, with an Overweight rating, indicating a strong buy opportunity.
AbCellera Biologics has experienced a massive run, with the stock up almost 300%, and has the potential for an even bigger increase, with some analysts predicting a 400% YTD gain.
The company has a strong management team, fundamentals, and research in place, making it a solid investment opportunity, and recent news, such as a presentation at the 2026 IMS Menopause Convention Conference, could lead to even more gains.

Bearish· Aug 14

$ABCL insiders are buying shares at a 4-year high, indicating a potential reversal of their bullish sentiment and a possible "Dump" phase in the pump-and-dump scheme.
The company's 8% dilution through the sale of 200 million shares of company stock may have added no new value, and the insiders' buying may not be enough to offset the potential losses for short sellers.
The short interest of 48 million is a significant amount, and even with massive volumes, it may take time for the shorts to cover their positions, leading to a potentially wild market in the coming weeks.

Generated by AI

Topics

Of the messages about ABCL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	34.1%	17.17%	10.31%	29.19%
Announcements	64.74%	69.2%	61.85%	32.28%
Technical Analysis	1.15%	13.51%	19.22%	8.77%
Macro	0%	0.12%	7.11%	27.73%
Earnings	0%	0%	0.54%	1.79%
Controversies	0%	0%	0.97%	0.24%

Announcements· Aug 25

AbCellera Biologics Inc. ($ABCL) shares have surged +120.4% in the past month, with the company's stock price rising to $12.5, and investors who had invested $10,000 into $ABCL at IPO and held to today would currently have $2,049.
AbCellera has received a significant boost with its stock price rising due to the company's recent announcement of a $200M offering, which will give it additional capital to advance its clinical pipeline.
The company's Phase 2 results for ABCL635, which showed an 83% hot-flash reduction at Week 4, have been a major catalyst for the stock's price increase, with the company's stock price rising to $12.06, marking a significant double-digit gain for the session.

Technical Analysis· Aug 10

The $ABCL stock has shown a +35% increase after the CEO's announcement, and the stock has gapped up 30% before market open.
The stock has been in a triangle consolidation pattern, and the probability is pointing to continuation toward the upside.
The stock's RSI is at 79.2, indicating overbought conditions that often precede near-term consolidation, and the stock may be due for a pullback or consolidation.

Generated by AI

Community

Of the messages about ABCL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	82.34%	87.43%	79.05%	67.46%
Newcomers	17.66%	12.57%	20.95%	32.54%

Regulars· Sep 29

JPMorgan issues a $17 price target on ABCL, citing the company's multitude of partnerships as a validation of its underlying technology platform.
ABCL's AI is embedded in its discovery process, but the company lacks an open partnership with any frontier model or chip company, unlike some of its peers.
ABCL is on track to have 5 molecules in the clinic by mid-next year, with two programs currently in IND-enabling studies, and the company's stock has seen a significant increase in value following its lead NK3R antagonist internal program for menopausal hot flashes.

Newcomers· Sep 29

Newcomers to discussing ABCL are focused on its potential for explosive growth, with some predicting a price increase to $36-$52.
Others are noticing ABCL's strong momentum and good pipeline, leading them to buy in and speculate on further gains.
A few newcomers are also referencing the company's recent presentation at the IMS Menopause Convention and the potential for a breakout above resistance at $15.

Generated by AI

News

ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know

AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.

7d agoYahoo Finance

AbCellera and Recursion Pharmaceuticals: two AI-drug stocks, two different stories

11d agoInvesting.com

Also Discussed

Investors talking about ABCL also mention

#	Name	Attention
1	Absci CorporationABSI	0%+0
2	Schrödinger, Inc.SDGR	0%-0.01
3	Relay Therapeutics Inc.RLAY	0%new
4	EXAI - Exscientia plc	——
5	Recursion Pharmaceuticals, Inc. Class A Common StockRXRX	0.01%+0
6	Prime Medicine, Inc.PRME	0%-0.01
7	MindWalk Holdings Corp.IPA	0%0
8	BioAge Labs, Inc.BIOA	0%-0.13
9	10x Genomics Inc. Class A Common StockTXG	0%-0.02
10	UFP Technologies Inc.UFPT	0%0

AbCellera Biologics Inc.

Healthcare
Biotechnology

AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines. Its platform combines biology, computation, engineering, and data science to identify rare and potent antibodies from natural immune responses and advance them into drug programs. The company’s current work spans endocrinology and women’s health, immunology, oncology, and inflammation-related diseases, reflecting a broad therapeutic focus. AbCellera Biologics Inc. also develops an internal pipeline of antibody candidates and collaborates with biopharmaceutical partners on discovery and development programs. Its capabilities extend from target identification and antibody discovery through clinical manufacturing support, making it an integrated player in the antibody therapeutics market.

Website

Location

150 West 4th Ave

Vancouver, BC, V5Y 1G6

Canada

Social

What share of all stock conversation is about ABCL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.24% -0.06	0.13% +0.05	0.07% -0.07	0.03% -0.01

Sep 29

JPMorgan initiates coverage of AbCellera with an Overweight rating and a $17 price target, citing the company's differentiated technology platform and partnerships.
AbCellera's lead NK3R antagonist internal program for menopausal hot flashes has shown strong efficacy and safety results, with the firm believing the stock "stands at a major value inflection point".
AbCellera aims to have 5 molecules in the clinic by the middle of next year, with 4 more programs than currently in the clinic, and is making progress in IND-enabling studies.

Generated by AI

Sentiment

Of the messages about ABCL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	98.39% +27.56	89.56% -6.43	90.35% +2.35	91.42% -3.21
Bearish	1.61% -27.56	10.44% +6.43	9.65% -2.35	8.58% +3.21

Bullish· Sep 29

JPMorgan has initiated a price target of $17 for AbCellera Biologics, with an Overweight rating, indicating a strong buy opportunity.
AbCellera Biologics has experienced a massive run, with the stock up almost 300%, and has the potential for an even bigger increase, with some analysts predicting a 400% YTD gain.
The company has a strong management team, fundamentals, and research in place, making it a solid investment opportunity, and recent news, such as a presentation at the 2026 IMS Menopause Convention Conference, could lead to even more gains.

Bearish· Aug 14

$ABCL insiders are buying shares at a 4-year high, indicating a potential reversal of their bullish sentiment and a possible "Dump" phase in the pump-and-dump scheme.
The company's 8% dilution through the sale of 200 million shares of company stock may have added no new value, and the insiders' buying may not be enough to offset the potential losses for short sellers.
The short interest of 48 million is a significant amount, and even with massive volumes, it may take time for the shorts to cover their positions, leading to a potentially wild market in the coming weeks.

Generated by AI

Topics

Of the messages about ABCL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	34.1%	17.17%	10.31%	29.19%
Announcements	64.74%	69.2%	61.85%	32.28%
Technical Analysis	1.15%	13.51%	19.22%	8.77%
Macro	0%	0.12%	7.11%	27.73%
Earnings	0%	0%	0.54%	1.79%
Controversies	0%	0%	0.97%	0.24%

Announcements· Aug 25

AbCellera Biologics Inc. ($ABCL) shares have surged +120.4% in the past month, with the company's stock price rising to $12.5, and investors who had invested $10,000 into $ABCL at IPO and held to today would currently have $2,049.
AbCellera has received a significant boost with its stock price rising due to the company's recent announcement of a $200M offering, which will give it additional capital to advance its clinical pipeline.
The company's Phase 2 results for ABCL635, which showed an 83% hot-flash reduction at Week 4, have been a major catalyst for the stock's price increase, with the company's stock price rising to $12.06, marking a significant double-digit gain for the session.

Technical Analysis· Aug 10

The $ABCL stock has shown a +35% increase after the CEO's announcement, and the stock has gapped up 30% before market open.
The stock has been in a triangle consolidation pattern, and the probability is pointing to continuation toward the upside.
The stock's RSI is at 79.2, indicating overbought conditions that often precede near-term consolidation, and the stock may be due for a pullback or consolidation.

Generated by AI

Community

Of the messages about ABCL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	82.34%	87.43%	79.05%	67.46%
Newcomers	17.66%	12.57%	20.95%	32.54%

Regulars· Sep 29

JPMorgan issues a $17 price target on ABCL, citing the company's multitude of partnerships as a validation of its underlying technology platform.
ABCL's AI is embedded in its discovery process, but the company lacks an open partnership with any frontier model or chip company, unlike some of its peers.
ABCL is on track to have 5 molecules in the clinic by mid-next year, with two programs currently in IND-enabling studies, and the company's stock has seen a significant increase in value following its lead NK3R antagonist internal program for menopausal hot flashes.

Newcomers· Sep 29

Newcomers to discussing ABCL are focused on its potential for explosive growth, with some predicting a price increase to $36-$52.
Others are noticing ABCL's strong momentum and good pipeline, leading them to buy in and speculate on further gains.
A few newcomers are also referencing the company's recent presentation at the IMS Menopause Convention and the potential for a breakout above resistance at $15.

Generated by AI

AbCellera Biologics

Social

Sep 29

Bullish· Sep 29

Bearish· Aug 14

Announcements· Aug 25

Technical Analysis· Aug 10

Regulars· Sep 29

Newcomers· Sep 29

JPMorgan initiates AbCellera stock coverage with overweight rating

Why is Abcellera Biologics stock climbing today?

Abcellera Biologics stock hits 52-week high at 13.23 USD

Goldman Sachs resumes AbCellera stock coverage with neutral rating

ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know

AbCellera and Recursion Pharmaceuticals: two AI-drug stocks, two different stories

Also Discussed

AbCellera Biologics Inc.

Company Information

Location

JPMorgan initiates AbCellera stock coverage with overweight rating

Why is Abcellera Biologics stock climbing today?

Abcellera Biologics stock hits 52-week high at 13.23 USD

Goldman Sachs resumes AbCellera stock coverage with neutral rating

ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know

AbCellera and Recursion Pharmaceuticals: two AI-drug stocks, two different stories

Also Discussed

Social

Sep 29

Bullish· Sep 29

Bearish· Aug 14

Announcements· Aug 25

Technical Analysis· Aug 10

Regulars· Sep 29

Newcomers· Sep 29